The Role of Medicinal Mushrooms in Brain Cancer Therapies: Review

Gargano, Maria Letizia; Venturella, Giuseppe; Bosco, Filippo; Fabrini, Maria Grazia; Gao, Wenyuan; Pecoraro, Vincent L.

doi:10.1615/intjmedmushrooms.2021038277

Cited by 7 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Schizophyllum commune, which accounted for 5.26% of the total isolated strains in this study, was recently found to cause mycotic disease in people on a rare basis, especially via cutaneous infection [ 62 ]. Although this fungal species is not commonly considered as pathogenic to humans, being mostly regarded as a medicinal mushroom [ 63 ], S. commune was indicated as a possible cause of pulmonary basidiomycosis by Unno et al [ 64 ], while inhalation of S. commune spores has been recently linked to allergic bronchopulmonary mycosis (ABPM) or allergy-related bronchopulmonary infections and sinusitis [ 65 , 66 ]. Furthermore, S. commune infection cases have increased significantly in the last few decades, since the first case of onychomycosis described by Kligman in 1950 [ 67 ].…”

Section: Discussionmentioning

confidence: 99%

Analysis of Airborne Fungal Communities on Pedestrian Bridges in Urban Environments

Al-Shaarani,

Quach,

Wang

et al. 2023

Microorganisms

Self Cite

View full text Add to dashboard Cite

Airborne fungal spores constitute an important type of bioaerosol and are responsible for a number of negative effects on human health, including respiratory diseases and allergies. We investigated the diversity and concentration of culturable airborne fungi on pedestrian bridges in Tianjin, China, using an HAS-100B air sampler. We compared the airborne fungal communities at the top central area of the selected pedestrian bridges and along the corresponding sidewalk, at ground level. A total of 228 fungal strains belonging to 96 species and 58 genera of Ascomycota (68.86%), Basidiomycota (30.26%), and Mucoromycota (0.88%) were isolated and identified using morphological and molecular analysis. Alternaria was the dominant genus (20.61%), followed by Cladosporium (11.48%), Schizophyllum (6.14%), Sporobolomyces (5.70%), and Sporidiobolus (4.82%). Alternaria alternata was the most frequently occurring fungal species (6.58%), followed by Schizophyllum commune (5.26%), Alternaria sp. (4.82%), Sporobolomyces carnicolor (4.39%), and Cladosporium cladosporioides (3.95%). The recorded fungal concentration ranged from 10 to 180 CFU/m3. Although there was no significant difference in the distribution and abundance of the dominant airborne fungal taxa between the two investigated bridges’ sites, numerous species detected with a low percentage of abundance belonging to well-known pathogenic fungal genera, including Alternaria, Aspergillus, Aureobasidium, Cladosporium, Penicillium, and Trichoderma, were exclusively present in one of the two sites. The relative humidity showed a stronger influence compared to the temperature on the diversity and concentration of airborne fungi in the investigated sites. Our results may provide valuable information for air quality monitoring and for assessing human health risks associated with microbial pollution.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of Airborne Fungal Communities on Pedestrian Bridges in Urban Environments

Al-Shaarani,

Quach,

Wang

et al. 2023

Microorganisms

Self Cite

View full text Add to dashboard Cite

show abstract

“…Abbreviations: 1 nerve growth factor (NGF), 2 inducible nitric oxide synthase (iNOS), 3 mitogen-activated protein kinase (MAPK), 4 homologous protein (CHOP), 5 insulin-degrading enzyme (IDE), 6 Alzheimer's disease (AD), 7 8-hydroxy-2'-deoxyguanosine (8-OHdG), 8 thiobarbituric acid reactive (TBARS), 9 proliferating cell nuclear antigen (PCNA), 10 doublecortin (DCX), 11 interleukin 6 (IL-6), 12 cyclooxygenase-2 (COX-2), 13 superoxide dismutase 1 (SOD-1), 14 nuclear factor erythroid 2-related factor 2 (Nrf2), 15 N-methyl-D-aspartate receptor 1 (NMDAR1), 16 metabotropic glutamate receptor 2 (mGlutR2), 17 transforming growth factor beta 1 (TGF-beta1).…”

Section: Ergothioneine-enriched Primordiummentioning

confidence: 99%

“…IBD 15 Reducing the 5-Fu-induced GM dysbiosis, suppressing tumor growth, and inhibiting inflammatory markers. [120] Abbreviations: 1 H. erinaceus polysaccharides (HEPs), 2 shorty-chain fatty acid (SCFA), 3 H. erinaceus LGAM 4514 in 100% beech sawdust (HEBS), 4 H. erinaceus LGAM 4514 in olive pruning residues (HEOLRP), 5 gut microbiota (GM), 6 alkaline phosphatase (ALP), 7 low-density lipoprotein (LDL), 8 uric acid (UA), 9 creatinine (CREA), 10 body weight (Bw), 11 ulcerative colitis (UC), 12 purified unique polysaccharide isolated from H. erinaceus mycelium (EP-1), 13 dextran sulfate sodium (DSS), 14 low-weight polysaccharide from H. erinaceus with Mw: 9.9 kDa (HEP10), 15 intestinal bowel disease (IBD), 16 cyclophosphamide (CTX), 17 tight junctions (TJ), 18 mucin (MUC).…”

Section: Akkermansia Muciniphila Proteobacteriamentioning

confidence: 99%

See 1 more Smart Citation

Hericium erinaceus in Neurodegenerative Diseases: From Bench to Bedside and Beyond, How Far from the Shoreline?

Brandalise

Roda

Ratto

et al. 2023

JoF

Self Cite

View full text Add to dashboard Cite

A growing number of studies is focusing on the pharmacology and feasibility of bioactive compounds as a novel valuable approach to target a variety of human diseases related to neurological degeneration. Among the group of the so-called medicinal mushrooms (MMs), Hericium erinaceus has become one of the most promising candidates. In fact, some of the bioactive compounds extracted from H. erinaceus have been shown to recover, or at least ameliorate, a wide range of pathological brain conditions such as Alzheimer’s disease, depression, Parkinson’s disease, and spinal cord injury. In a large body of in vitro and in vivo preclinical studies on the central nervous system (CNS), the effects of erinacines have been correlated with a significant increase in the production of neurotrophic factors. Despite the promising outcome of preclinical investigations, only a limited number of clinical trials have been carried out so far in different neurological conditions. In this survey, we summarized the current state of knowledge on H. erinaceus dietary supplementation and its therapeutic potential in clinical settings. The bulk collected evidence underlies the urgent need to carry out further/wider clinical trials to prove the safety and efficacy of H. erinaceus supplementation, offering significant neuroprotective applications in brain pathologies.

show abstract